Medspas are leading the charge in offering GLP-1 treatments, with 60% of medspas in the U.S. now providing these services, compared to 35% of aesthetic physician offices. Average spend per patient ...
British fund manager Terry Smith has sold his stake in Diageo Plc, citing concerns about the management of the drinks company ...
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...
Diet food brands have been hit in recent years, but now GLP-1 drugs like Ozempic are hitting the market, will this spell the ...
Financial writer recommends buying LifeVantage stock after exceeding Q2/FY2025 expectations with new MindBody GLP-1 System launch.
Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...
Maridebart cafraglutide, a novel injectable GIP receptor antagonist/GLP-1 receptor agonist, reduced body weight by ...
Jonathan Van Ness is seen on the Netflix show, Queer Eye. He has, for the first time, spoken publicly about using weight loss ...
Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...
Over her three-decade career, weight management physician Dr. Sarah Ro has seen hundreds of patients. Many of them are on ...
"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...
Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback